Xiankun Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiankun Sun has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Zhiwen Chen
Department of Nephrology West China Hospital, Sichuan University/West China School of Nursing, Sichuan University Chengdu Sichuan China
6 shared publications- Fang Wang
Department of Nephrology West China Hospital, Sichuan University/West China School of Nursing, Sichuan University Chengdu Sichuan China
5 shared publications Ling Zhang
Department of Nephrology and Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China
4 shared publicationsLi Lin
Department of Nephrology West China Hospital, Sichuan University/West China School of Nursing, Sichuan University Chengdu Sichuan China
3 shared publications- Ling Zhang
Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University
3 shared publications Xue Tang
Department of Nephrology West China Hospital, Sichuan University/West China School of Nursing, Sichuan University Chengdu Sichuan China
3 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Wiley in Seminars in Dialysis
- Vol. 39 (4) , 177-184
Antimicrobial Glucose Chlorhexidine Dressings vs. Sterile Dressings in Preventing Catheter‐Related Infections During Continuous Renal Replacement Therapy: A Randomized Controlled Trial
Background: Catheter‐related bloodstream infections (CRBSIs) are a major cause of complications in critically ill patients receiving continuous renal replacement therapy (CRRT), especially those with nontunneled catheters. These infections can lead to longer hospital stays, higher costs, and worse patient outcomes. Although sterile dressings are commonly used to prevent CRBSIs, antimicrobial dressings, such as those containing chlorhexidine, may offer better protection. This study aimed to compare the effectiveness of antimicrobial glucose chlorhexidine dressings and sterile dressings in preventing CRBSIs in patients receiving CRRT. Methods: A prospective, randomized controlled, single‐blind study was conducted. All participants were kept blinded to group assignment. We enrolled patients admitted to the Intensive Care Unit (ICU) of West China Hospital, Sichuan University between September 2022 and November 2023 who were scheduled for vascular catheter placement before receiving continuous renal replacement therapy (CRRT). The participants were randomly allocated to either the intervention group (receiving glucose chlorhexidine antimicrobial dressing) or the control group (receiving sterile dressing) via a random number table. The dressing was changed every 7 days for the glucose chlorhexidine antimicrobial group and every 48 h for the sterile dressing group, in accordance with the guideline. Dressings were replaced immediately if they became rolled, loose, or visibly soiled. The primary outcomes were the local infection rate at the catheter insertion site, suspected catheter‐related bloodstream infections (CRBSIs), incidence of CRBSIs, length of hospital stay, ICU stay duration, and hospital mortality rates. Results: A total of 520 patients were screened, and 410 patients were ultimately included in the study, with 205 patients in each group (glucose chlorhexidine antimicrobial dressing group and sterile dressing group). The incidence of local infection at the catheter insertion site was 40.0% in the sterile dressing group, which was significantly greater than the 15.6% reported in the glucose chlorhexidine antimicrobial dressing group ( p < 0.001). The total CRBSI rate in the intervention group was significantly lower (6.3%) than that in the control group (13.7%) ( p = 0.014). No significant differences were found between the two groups in terms of suspected catheter‐related bloodstream infections (CRBSIs), CRBSI incidence, length of hospital stay, ICU stay duration, or hospital mortality rates ( p > 0.05). The Cox proportional hazards model suggested that patients in the control group were at a substantially greater risk of local infections and CRBSIs over time than those in the intervention group. Conclusion: Glucose chlorhexidine antimicrobial dressings significantly reduce catheter insertion site infections and overall CRBSI incidence, demonstrating their clinical value in preventing infection in patients receiving CRRT.
- 31 July 2026
- Published by Wiley in Seminars in Dialysis
- Vol. 39 (4) , 177-184
Open AccessAntimicrobial Glucose Chlorhexidine Dressings vs. Sterile Dressings in Preventing Catheter‐Related Infections During Continuous Renal Replacement Therapy: A Randomized Controlled Trial
Background: Catheter‐related bloodstream infections (CRBSIs) are a major cause of complications in critically ill patients receiving continuous renal replacement therapy (CRRT), especially those with nontunneled catheters. These infections can lead to longer hospital stays, higher costs, and worse patient outcomes. Although sterile dressings are commonly used to prevent CRBSIs, antimicrobial dressings, such as those containing chlorhexidine, may offer better protection. This study aimed to compare the effectiveness of antimicrobial glucose chlorhexidine dressings and sterile dressings in preventing CRBSIs in patients receiving CRRT. Methods: A prospective, randomized controlled, single‐blind study was conducted. All participants were kept blinded to group assignment. We enrolled patients admitted to the Intensive Care Unit (ICU) of West China Hospital, Sichuan University between September 2022 and November 2023 who were scheduled for vascular catheter placement before receiving continuous renal replacement therapy (CRRT). The participants were randomly allocated to either the intervention group (receiving glucose chlorhexidine antimicrobial dressing) or the control group (receiving sterile dressing) via a random number table. The dressing was changed every 7 days for the glucose chlorhexidine antimicrobial group and every 48 h for the sterile dressing group, in accordance with the guideline. Dressings were replaced immediately if they became rolled, loose, or visibly soiled. The primary outcomes were the local infection rate at the catheter insertion site, suspected catheter‐related bloodstream infections (CRBSIs), incidence of CRBSIs, length of hospital stay, ICU stay duration, and hospital mortality rates. Results: A total of 520 patients were screened, and 410 patients were ultimately included in the study, with 205 patients in each group (glucose chlorhexidine antimicrobial dressing group and sterile dressing group). The incidence of local infection at the catheter insertion site was 40.0% in the sterile dressing group, which was significantly greater than the 15.6% reported in the glucose chlorhexidine antimicrobial dressing group ( p < 0.001). The total CRBSI rate in the intervention group was significantly lower (6.3%) than that in the control group (13.7%) ( p = 0.014). No significant differences were found between the two groups in terms of suspected catheter‐related bloodstream infections (CRBSIs), CRBSI incidence, length of hospital stay, ICU stay duration, or hospital mortality rates ( p > 0.05). The Cox proportional hazards model suggested that patients in the control group were at a substantially greater risk of local infections and CRBSIs over time than those in the intervention group. Conclusion: Glucose chlorhexidine antimicrobial dressings significantly reduce catheter insertion site infections and overall CRBSI incidence, demonstrating their clinical value in preventing infection in patients receiving CRRT.
- 9 April 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (2) , e70121
Double Plasma Molecular Adsorption System Plus Sequential Half‐Dose Plasmapheresis in Tandem With Continuous Renal Replacement Therapy: A Case Report
A 48‐year‐old male patient was diagnosed with critical acute pancreatitis, renal dysfunction and liver dysfunction. Because of the presence of multiorgan dysfunction, continuous renal replacement therapy (CRRT) was required on the first day of the patient's admission to the ICU in order to help stabilize the patient's internal environment. Meanwhile, the patient also received a total of five double plasma molecular adsorption system plus sequential half‐dose plasmapheresis (DPMAS‐PE) treatments, of which the first, fourth, and fifth DPMAS‐PE treatments were chosen to be administered concurrently with CRRT. This report is to clarify how four CRRT machines using three parallel modalities successfully completed DPMAS‐PE in tandem with CRRT (DPMAS‐PE‐CRRT). Furthermore, DPMAS‐PE‐CRRT showed similar effectiveness in removing total bilirubin and total bile acid when compared to nonparallel CRRT. During the parallel therapy, there were no serious adverse reactions. To validate this case, more clinical trials are needed.
- 9 April 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (2) , e70121
Double Plasma Molecular Adsorption System Plus Sequential Half‐Dose Plasmapheresis in Tandem With Continuous Renal Replacement Therapy: A Case Report
A 48‐year‐old male patient was diagnosed with critical acute pancreatitis, renal dysfunction and liver dysfunction. Because of the presence of multiorgan dysfunction, continuous renal replacement therapy (CRRT) was required on the first day of the patient's admission to the ICU in order to help stabilize the patient's internal environment. Meanwhile, the patient also received a total of five double plasma molecular adsorption system plus sequential half‐dose plasmapheresis (DPMAS‐PE) treatments, of which the first, fourth, and fifth DPMAS‐PE treatments were chosen to be administered concurrently with CRRT. This report is to clarify how four CRRT machines using three parallel modalities successfully completed DPMAS‐PE in tandem with CRRT (DPMAS‐PE‐CRRT). Furthermore, DPMAS‐PE‐CRRT showed similar effectiveness in removing total bilirubin and total bile acid when compared to nonparallel CRRT. During the parallel therapy, there were no serious adverse reactions. To validate this case, more clinical trials are needed.
- 24 February 2026
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 49 (2) , 108-114
Application of the CA330 cytokine adsorption cartridge for coupled plasma filtration adsorption therapy in severe acute pancreatitis-induced cytokine storm: A case report
This case describes an 82-year-old male patient presenting with persistent upper abdominal colic, diagnosed as severe acute pancreatitis. The patient then suffered a cytokine storm, as well as renal dysfunction. Therefore, the patient underwent two sessions of coupled plasma filtration adsorption (CPFA) therapy utilising the CA330 cytokine adsorption cartridge as the adsorbent. The first CPFA session lasted 8 h, followed by a 4-h interval (during which continuous veno-venous haemodialysis therapy was provided), and the second 8-h CPFA session started. Due to family requests and comprehensive consideration by the medical team, the second CPFA session was extended to 20 h. Ultimately, the patient was weaned off blood purification therapy (43 h after its initiation). The study demonstrated a significant reduction in cytokine levels as the course of treatment increased. However, beyond a specific threshold, cytokine adsorption may reach saturation. The medicinal applications of CPFA (particularly CA330) deserve more investigation.
- 24 February 2026
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 49 (2) , 108-114
Application of the CA330 cytokine adsorption cartridge for coupled plasma filtration adsorption therapy in severe acute pancreatitis-induced cytokine storm: A case report
This case describes an 82-year-old male patient presenting with persistent upper abdominal colic, diagnosed as severe acute pancreatitis. The patient then suffered a cytokine storm, as well as renal dysfunction. Therefore, the patient underwent two sessions of coupled plasma filtration adsorption (CPFA) therapy utilising the CA330 cytokine adsorption cartridge as the adsorbent. The first CPFA session lasted 8 h, followed by a 4-h interval (during which continuous veno-venous haemodialysis therapy was provided), and the second 8-h CPFA session started. Due to family requests and comprehensive consideration by the medical team, the second CPFA session was extended to 20 h. Ultimately, the patient was weaned off blood purification therapy (43 h after its initiation). The study demonstrated a significant reduction in cytokine levels as the course of treatment increased. However, beyond a specific threshold, cytokine adsorption may reach saturation. The medicinal applications of CPFA (particularly CA330) deserve more investigation.
- 10 April 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (2) , e70019
Efficacy and Safety of Double Plasma Molecular Adsorption System at Different Therapeutic Doses During Regional Citrate Anticoagulation: A Pilot Study
This study aimed to assess the safety and therapeutic efficacy of increasing the dosage of the double plasma molecular adsorption system (DPMAS) in patients with liver failure during regional citrate anticoagulation (RCA). A prospective nonrandomized controlled trial was conducted. Three groups (3 L group, 4.5 L group, and 6 L group) of patients with liver failure receiving DPMAS treatment were created on the basis of various therapeutic plasma volumes. A total of 303 patients were included, with 110 in the 3 L group, 121 in the 4.5 L group, and 72 in the 6 L group. At the end of treatment, there was a statistically significant difference in the bilirubin clearance rate among the groups (H = 15.239, p < 0.001). Pairwise comparisons revealed that only the difference in the bilirubin clearance rates between the 6 L group and the 3 L group was statistically significant (p < 0.001). With the exception of base excess, no statistically significant differences were found between these three groups for any of the relevant laboratory indicators (p > 0.05). The incidence of hypotension, hypocalcemia, acidosis, alkalosis, hypernatremia, hyperlactatemia, and allergic reactions did not differ significantly among these three groups (p > 0.05). Furthermore, a statistically significant difference was found in clotting events among these three groups (p = 0.027), with a higher incidence observed in the 6 L group than in the 3 L group (p = 0.011). Increasing the therapeutic dose of RCA‐DPMAS further removed bilirubin and did not increase the complications associated with citrate anticoagulation, but the coagulation risk is a concern.
- 10 April 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (2) , e70019
Efficacy and Safety of Double Plasma Molecular Adsorption System at Different Therapeutic Doses During Regional Citrate Anticoagulation: A Pilot Study
This study aimed to assess the safety and therapeutic efficacy of increasing the dosage of the double plasma molecular adsorption system (DPMAS) in patients with liver failure during regional citrate anticoagulation (RCA). A prospective nonrandomized controlled trial was conducted. Three groups (3 L group, 4.5 L group, and 6 L group) of patients with liver failure receiving DPMAS treatment were created on the basis of various therapeutic plasma volumes. A total of 303 patients were included, with 110 in the 3 L group, 121 in the 4.5 L group, and 72 in the 6 L group. At the end of treatment, there was a statistically significant difference in the bilirubin clearance rate among the groups (H = 15.239, p < 0.001). Pairwise comparisons revealed that only the difference in the bilirubin clearance rates between the 6 L group and the 3 L group was statistically significant (p < 0.001). With the exception of base excess, no statistically significant differences were found between these three groups for any of the relevant laboratory indicators (p > 0.05). The incidence of hypotension, hypocalcemia, acidosis, alkalosis, hypernatremia, hyperlactatemia, and allergic reactions did not differ significantly among these three groups (p > 0.05). Furthermore, a statistically significant difference was found in clotting events among these three groups (p = 0.027), with a higher incidence observed in the 6 L group than in the 3 L group (p = 0.011). Increasing the therapeutic dose of RCA‐DPMAS further removed bilirubin and did not increase the complications associated with citrate anticoagulation, but the coagulation risk is a concern.
- 7 April 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (2) , e70021
Efficacy and Safety of Using Designed Auxiliary Lines in Standard CRRT Machines for DFPP Treatment
The demand for double‐filtration plasmapheresis (DFPP) in clinical settings is growing steadily, yet the range and availability of specialized equipment designed to support DFPP are relatively limited. We aimed to assess the efficacy and safety of a designed auxiliary line for DFPP treatment using standard continuous renal replacement treatment (CRRT) machines. This prospective self‐controlled study was conducted between May 2021 and April 2024. Patients who underwent DFPP treatment using both specialized DFPP machines and standard CRRT machines (using designed auxiliary line) were enrolled in the study. DFPP sessions were divided into the specialized DFPP machine group and the standard CRRT machine group. The rates of completed DFPP treatments, DFPP cost, circuit clotting, hypotension, anaphylaxis, hypocalcemia, and nurse operating time were compared. A total of 440 DFPP sessions were performed for 80 patients, with 330 (75.0%) sessions in the specialized DFPP machine group and 110 (25.0%) in the standard CRRT machine group. There were no statistically significant differences between the two groups in terms of the completed DFPP treatment rate (89.4% vs. 88.2%, p = 0.724), circuit clotting (8.2% vs. 7.3%, p = 0.760), anaphylaxis (12.7% vs. 11.8%, p = 0.803), hypotension (10.6% vs. 9.1%, p = 0.650), hypocalcemia (17.3% vs. 20.0%, p = 0.519), and nurse operation time (35.08 ± 2.27 min vs. 36.62 ± 1.94 min, p = 0.082). However, the cost per DFPP session in the standard CRRT machine group was lower than in the specialized DFPP machine (976.81 ± 14.38 $ vs. 1007.43 ± 35.30 $, p < 0.001). Standard CRRT machines can effectively and safely perform DFPP treatment using a specially designed auxiliary line, which is more cost‐effective. Even in primary hospitals without specialized DFPP machines, CRRT machines can be used to perform DFPP treatment.- 7 April 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (2) , e70021
Efficacy and Safety of Using Designed Auxiliary Lines in Standard CRRT Machines for DFPP Treatment
The demand for double‐filtration plasmapheresis (DFPP) in clinical settings is growing steadily, yet the range and availability of specialized equipment designed to support DFPP are relatively limited. We aimed to assess the efficacy and safety of a designed auxiliary line for DFPP treatment using standard continuous renal replacement treatment (CRRT) machines. This prospective self‐controlled study was conducted between May 2021 and April 2024. Patients who underwent DFPP treatment using both specialized DFPP machines and standard CRRT machines (using designed auxiliary line) were enrolled in the study. DFPP sessions were divided into the specialized DFPP machine group and the standard CRRT machine group. The rates of completed DFPP treatments, DFPP cost, circuit clotting, hypotension, anaphylaxis, hypocalcemia, and nurse operating time were compared. A total of 440 DFPP sessions were performed for 80 patients, with 330 (75.0%) sessions in the specialized DFPP machine group and 110 (25.0%) in the standard CRRT machine group. There were no statistically significant differences between the two groups in terms of the completed DFPP treatment rate (89.4% vs. 88.2%, p = 0.724), circuit clotting (8.2% vs. 7.3%, p = 0.760), anaphylaxis (12.7% vs. 11.8%, p = 0.803), hypotension (10.6% vs. 9.1%, p = 0.650), hypocalcemia (17.3% vs. 20.0%, p = 0.519), and nurse operation time (35.08 ± 2.27 min vs. 36.62 ± 1.94 min, p = 0.082). However, the cost per DFPP session in the standard CRRT machine group was lower than in the specialized DFPP machine (976.81 ± 14.38 $ vs. 1007.43 ± 35.30 $, p < 0.001). Standard CRRT machines can effectively and safely perform DFPP treatment using a specially designed auxiliary line, which is more cost‐effective. Even in primary hospitals without specialized DFPP machines, CRRT machines can be used to perform DFPP treatment.- Open Access
Integrative anticoagulation of nafamostat mesylate in double plasma molecular adsorption system plus sequential half-dose plasmapheresis for patients with liver failure: a randomised controlled trial protocol
Introduction Nafamostat mesylate (NM) is widely recognised as a premier anticoagulant, especially in Japan and Korea. However, it has not yet been used as an anticoagulant in double plasma molecular adsorption system (DPMAS) plus sequential half-dose plasmapheresis (PE) therapy. This study aims to comprehensively evaluate the safety and efficacy of NM-integrated anticoagulation during DPMAS plus sequential half-dose PE therapy for patients with liver failure. Methods and analysis A two-arm, open-label, parallel, randomised controlled trial involving 132 patients with liver failure will be conducted in China. Eligible participants will be randomly allocated to either the nafamostat mesylate integrative anticoagulation group or the heparin integrative anticoagulation group, employing a central randomisation system at a 1:1 ratio throughout the course of DPMAS plus sequential half-dose PE therapy. The primary outcome includes the number of successfully completed DPMAS plus sequential half-dose PE therapy. The secondary outcomes include liver function indicators, extracorporeal circulation pressures, coagulation function parameters, all-cause mortality rates and survival rates. Clinical safety will be assessed by analysis of the number of bleeding events, the number of clotting events and adverse events. Outcome analyses will be performed on both the intention-to-treat population, which includes all patients randomised, and the per-protocol population, which includes eligible patients who adhere to the planned treatment and follow-ups. Ethics and dissemination The trial protocol was approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University (approval number (2022)860). During the protocol revision process, all changes were reexamined and reapproved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University. The results will be presented at national and international conferences and published in peer-reviewed journals. Trial registration number ChiCTR2200064725.
Open AccessIntegrative anticoagulation of nafamostat mesylate in double plasma molecular adsorption system plus sequential half-dose plasmapheresis for patients with liver failure: a randomised controlled trial protocol
Introduction Nafamostat mesylate (NM) is widely recognised as a premier anticoagulant, especially in Japan and Korea. However, it has not yet been used as an anticoagulant in double plasma molecular adsorption system (DPMAS) plus sequential half-dose plasmapheresis (PE) therapy. This study aims to comprehensively evaluate the safety and efficacy of NM-integrated anticoagulation during DPMAS plus sequential half-dose PE therapy for patients with liver failure. Methods and analysis A two-arm, open-label, parallel, randomised controlled trial involving 132 patients with liver failure will be conducted in China. Eligible participants will be randomly allocated to either the nafamostat mesylate integrative anticoagulation group or the heparin integrative anticoagulation group, employing a central randomisation system at a 1:1 ratio throughout the course of DPMAS plus sequential half-dose PE therapy. The primary outcome includes the number of successfully completed DPMAS plus sequential half-dose PE therapy. The secondary outcomes include liver function indicators, extracorporeal circulation pressures, coagulation function parameters, all-cause mortality rates and survival rates. Clinical safety will be assessed by analysis of the number of bleeding events, the number of clotting events and adverse events. Outcome analyses will be performed on both the intention-to-treat population, which includes all patients randomised, and the per-protocol population, which includes eligible patients who adhere to the planned treatment and follow-ups. Ethics and dissemination The trial protocol was approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University (approval number (2022)860). During the protocol revision process, all changes were reexamined and reapproved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University. The results will be presented at national and international conferences and published in peer-reviewed journals. Trial registration number ChiCTR2200064725.
- 21 August 2024
- Published by Wiley in Seminars in Dialysis
- Vol. 37 (6) , 466-470
Continuous Renal Replacement Therapy Needs Its Own Circuit Diagram
- 21 August 2024
- Published by Wiley in Seminars in Dialysis
- Vol. 37 (6) , 466-470
Continuous Renal Replacement Therapy Needs Its Own Circuit Diagram
- Open Access
- 5 May 2022
- Published by Wiley in International Wound Journal
- Vol. 19 (8) , 2200-2209
Efficacy and safety of topical oxygen therapy for diabetic foot ulcers: An updated systematic review and meta‐analysis
To evaluate the efficacy and safety of topical oxygen therapy (TOT) in diabetic foot ulcers (DFUs), researchers systematically retrieved relevant studies from PubMed, EMBASE, Web of Science, CENTRAL and ClinicalTrials.gov. Relevant studies were searched from database inception to January 2022. Two researchers independently screened the literature, extracted data and assessed the quality of the included studies. Statistical analysis was performed in Stata 16.0. A total of seven RCTs involving 614 participants were included. Compared with the control group, the TOT group had a higher healing rate (RR = 1.63, 95% CI [1.33, 2.00]). According to descriptive analysis, TOT reduced the ulcer area and improved healing durability and quality of life. Furthermore, it had no effect on the occurrence of adverse events. However, it was unclear whether it would be able to reduce the healing time. The existing evidence suggests that TOT is effective and safe for chronic DFUs. Further studies are warranted to validate our findings.
- 5 May 2022
- Published by Wiley in International Wound Journal
- Vol. 19 (8) , 2200-2209
Open AccessEfficacy and safety of topical oxygen therapy for diabetic foot ulcers: An updated systematic review and meta‐analysis
To evaluate the efficacy and safety of topical oxygen therapy (TOT) in diabetic foot ulcers (DFUs), researchers systematically retrieved relevant studies from PubMed, EMBASE, Web of Science, CENTRAL and ClinicalTrials.gov. Relevant studies were searched from database inception to January 2022. Two researchers independently screened the literature, extracted data and assessed the quality of the included studies. Statistical analysis was performed in Stata 16.0. A total of seven RCTs involving 614 participants were included. Compared with the control group, the TOT group had a higher healing rate (RR = 1.63, 95% CI [1.33, 2.00]). According to descriptive analysis, TOT reduced the ulcer area and improved healing durability and quality of life. Furthermore, it had no effect on the occurrence of adverse events. However, it was unclear whether it would be able to reduce the healing time. The existing evidence suggests that TOT is effective and safe for chronic DFUs. Further studies are warranted to validate our findings.